Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Von Willebrand Disease, Type 3
Conditions
Von Willebrand Disease, Type 3
Trial Timeline
Apr 29, 2025 → Nov 1, 2026
NCT ID
NCT06883240About Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate is a pre-clinical stage product being developed by Roche for Von Willebrand Disease, Type 3. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06883240. Target conditions include Von Willebrand Disease, Type 3.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06883240 | Pre-clinical | Recruiting |
Competing Products
14 competing products in Von Willebrand Disease, Type 3
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents | Roche | Phase 3 | 77 |
| Neumega (Oprelvekin, Interleukin 11, IL-11) | Pfizer | Phase 2 | 51 |
| Oprelvekin, Interleukin 11, IL-11 | Pfizer | Phase 2 | 51 |
| recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11 | Pfizer | Phase 2 | 51 |
| efanesoctocog alfa (BIVV001) | Sanofi | Phase 1 | 32 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento® | CSL | Pre-clinical | 22 |
| Blood coagulation Factor VIII and vWF, human | CSL | Approved | 84 |
| Biostate® + Biostate® | CSL | Phase 2/3 | 64 |
| VWF/FVIII products | CSL | Pre-clinical | 22 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento | CSL | Approved | 84 |
| Alphanate SD/HT | Grifols | Approved | 82 |
| plasma-derived FVIII/VWF concentrate | Grifols | Approved | 82 |